Stockreport

Sanofi graft-versus-host disease asset Rezurock gains EU approval recommendation [Seeking Alpha]

Sanofi - American Depositary Shares  (SNY) 
US:NYSE Investor Relations: sanofi.com/en/investors
PDF approval to Sanofi's ( SNY ) chronic graft-versus-host disease treatment Rezurock (belumosudil). The recommendation is for use of Rezurock when other treatments have f [Read more]